このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

局所進行性または転移性の固形または原発性 CNS 腫瘍および/または満足のいく治療選択肢がない小児および青年におけるエントレクチニブ (Rxdx-101) の研究 (STARTRK-NG)

2026年9月18日 更新者:Hoffmann-La Roche

局所進行性または転移性の固形または原発性 CNS 腫瘍および/または満足のいく治療選択肢がない小児科における Entrectinib (Rxdx-101) の第 1/2 相、非盲検、用量漸増および拡大研究

This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.

調査の概要

状態

積極的、募集していない

介入・治療

研究の種類

介入

入学 (実際)

69

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • California
      • La Jolla、California、アメリカ、92093-0706
        • University of California San Diego
      • San Francisco、California、アメリカ、94158
        • UCSF Benioff Children's Hospital
    • Colorado
      • Aurora、Colorado、アメリカ、80045
        • Children's Hospital Colorado
    • Georgia
      • Atlanta、Georgia、アメリカ、30322
        • Egleston Children's Hospital at Emory University Atlanta
    • Illinois
      • Chicago、Illinois、アメリカ、60637
        • University of Chicago
    • Maryland
      • Baltimore、Maryland、アメリカ、21205
        • Johns Hopkins University
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02215
        • Dana Farber Cancer Institute
    • Missouri
      • St Louis、Missouri、アメリカ、63110
        • Washington University,St. Louis Children's Hospital
    • New York
      • New York、New York、アメリカ、10065
        • Memorial Sloan Kettering Cancer Center
    • Ohio
      • Columbus、Ohio、アメリカ、43205
        • Nationwide Children's Hospital
    • Oregon
      • Portland、Oregon、アメリカ、97239
        • Oregon Health & Science Uni
    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19104
        • Children's Hospital of Philadelphia
    • Tennessee
      • Memphis、Tennessee、アメリカ、38105
        • St. Jude Children'S Research Hospital
    • Texas
      • Houston、Texas、アメリカ、77030
        • Texas Children's Cancer and Hematology Center
    • Utah
      • Salt Lake City、Utah、アメリカ、84113
        • Primary Children's Hospital
      • London、イギリス、SW3 6JJ
        • Royal Marsden Hospital (Sutton)
      • Newcastle upon Tyne、イギリス、NE1 4LP
        • Royal Victoria Infirmary
    • Lombardy
      • Milan、Lombardy、イタリア、20133
        • Fondazione IRCCS Istituto Nazionale dei Tumori
    • Ontario
      • Toronto、Ontario、カナダ、M5G 1X8
        • The Hospital for Sick Children
      • Madrid、スペイン、28009
        • Hospital Infantil Universitario Nino Jesus
    • Baden-Wurttemberg
      • Heidelberg、Baden-Wurttemberg、ドイツ、69120
        • Universitaetsklinikum Heidelberg
      • Lyon、フランス、69373
        • Centre Leon Berard
      • Marseille、フランス、13385
        • Hôpital de la Timone, Oncologie Pédiatrique
      • Beijing、中国
        • Beijing Children's Hospital, Capital Medical University
    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200082
        • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
      • Hong Kong、香港、00000
        • Hong Kong Children's Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

1秒~18年 (子、大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Disease status:

    • Phase 1 portion (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1

    • Phase 2 portion:

      • Part B: Participants must have measurable or evaluable disease, as defined by RANO
      • Part C (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale
      • Part D: Participants must have measurable or evaluable disease, as defined by RECIST v1.1
      • Part E (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale or RANO
  2. Tumor type:

    • Phase 1 portion:

      * Part A: Relapsed or refractory extracranial solid tumors

    • Phase 2 portion

      • Part B: Primary brain tumors with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
      • Part D: Extracranial solid tumors (including NB) with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
  3. Histologic/molecular diagnosis of malignancy at diagnosis or the time of relapse

  4. Archival tumor tissue from diagnosis or, preferably, at relapse

  5. Performance status: Lansky or Karnofsky score ≥ 60% and minimum life expectancy of at least 4 weeks

  6. Prior therapy: Participants must have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options for solid tumors and primary CNS tumors that are neurotrophic tyrosine receptor kinase (NTRK) or ROS1 fusion-positive

  7. Participants must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to enrollment

  8. Adequate organ and neurologic function

  9. Females of childbearing potential must have a negative serum pregnancy test during screening and be neither breastfeeding nor intending to become pregnant during study participation. Agreement to remain abstinent or use use combined contraceptive methods prior to study entry, for the duration of study participation and in the following 90 days after discontinuation of study treatment.

  10. For male participants with a female partner of childbearing potential or a pregnant female partner: Agreement to remain abstinent or use a condom during the treatment period and for at least 3 months after the last dose of study drug

Exclusion Criteria:

  1. Receiving other experimental therapy
  2. Known congenital long QT syndrome
  3. History of recent (3 months) symptomatic congestive heart failure or ejection fraction ≤50% at screening
  4. Known active infections
  5. Familial or personal history of congenital bone disorders, bone metabolism alterations or osteopenia
  6. Receiving Enzyme Inducing Antiepileptic Drugs (EIAEDs) within 14 days of first dose.
  7. Prior treatment with approved or investigational TRK or ROS1 inhibitors
  8. Known hypersensitivity to entrectinib or any of the other excipients of the investigational medicinal product
  9. Patients with NB with bone marrow space-only disease
  10. Incomplete recovery from acute effects of any surgery prior to treatment.
  11. Active gastrointestinal disease or other malabsorption syndromes that would impact drug absorption.
  12. Other severe acute or chronic medical or psychiatric condition or lab abnormality that may increase the risk associated with study participation, drug administration or may interfere with the interpretation of study results.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Extracranial solid tumors harboring NTRK1/2/3,

Arm closed for further enrollment

ROS1, ALK non-gene fusion molecular alterations

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

他の名前:
  • RXDX-101
アクティブコンパレータ:CNS tumors harboring- NTRK1/2/3, ROS1, ALK

Arm closed for further enrollment

molecular alterations, including gene fusions

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

他の名前:
  • RXDX-101
アクティブコンパレータ:Neuroblastoma

Arm closed for further enrollment

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

他の名前:
  • RXDX-101
アクティブコンパレータ:Non-neuroblastoma, extracranial solid tumors

Arm closed for further enrollment

harboring - NTRK1/2/3, ROS1, ALK gene fusions

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

他の名前:
  • RXDX-101
アクティブコンパレータ:Any participant unable to swallow capsules

Arm closed for further enrollment

Any participant who otherwise meet all other eligibility criteria

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

他の名前:
  • RXDX-101
アクティブコンパレータ:Expansion: CNS tumors harboring NTRK1/2/3, ROS1

gene fusions

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

他の名前:
  • RXDX-101
アクティブコンパレータ:Expansion: Extracranial solid tumors harboring NTRK1/2/3, ROS1

NTRK 1,2,3 and ROS1 fusions

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

他の名前:
  • RXDX-101

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Maximum Tolerated Dose (MTD)
時間枠:Approximately 6 months

Assessed by National Cancer Institute Common Terminology for Adverse Events Criteria (NCI CTCAE v4.03)

Approximately 6 months
Recommended Phase 2 Dose (RP2D) of F1 Formulation In Pediatric Participants Able To Swallow Intact Capsules
時間枠:Approximately 6 months

Assessed by NCI CTCAE v4.03

Approximately 6 months
Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric Participants Able To Swallow Intact Capsules
時間枠:Approximately 6 months

Assessed by NCI CTCAE v4.03

Approximately 6 months
Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric In Participants Dosed Via Feeding Tube (Nasogastric Tube Or Gastric Tube)
時間枠:Approximately 6 months

Assessed by NCI CTCAE v4.03

Approximately 6 months
Recommended Phase 2 Dose (RP2D) Of Minitablets/F15 Formulation In Pediatric Participants Unable To Swallow Intact Capsules
時間枠:Approximately 6 months

Assessed by NCI CTCAE v4.03

Approximately 6 months
Cohort B: Objective Response Rate (ORR)
時間枠:Approximately 6 months

Assessed by RANO per the BICR

Approximately 6 months
Cohort D: ORR
時間枠:Approximately 6 months

Assessed by RECIST v1.1 per the BICR

Approximately 6 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Safety and Tolerability - AE, ECG and Labs assessed by NCI CTCAE v4.03
時間枠:Approximately 24 months

AE, ECG and Labs assessed by NCI CTCAE v4.03

Approximately 24 months
Maximum observed plasma drug concentration (Cmax) using F1 Formulation
時間枠:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Maximum observed plasma drug concentration (Cmax) using F06 Formulation given intact
時間枠:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Maximum observed plasma drug concentration (Cmax) using F06 Formulation administered via feeding tube
時間枠:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Maximum observed plasma drug concentration (Cmax) using minitablets/F15
時間枠:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Time to Cmax, by inspection (Tmax) using F1 Formulation
時間枠:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Time to Cmax, by inspection (Tmax) using F06 Formulation given intact
時間枠:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Time to Cmax, by inspection (Tmax) using F06 Formulation administered via feeding tube
時間枠:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Time to Cmax, by inspection (Tmax) using minitablets/F15
時間枠:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
AUC at steady state (AUCss) using F1 Formulation
時間枠:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
AUC at steady state (AUCss) using F06 Formulation given intact
時間枠:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
AUC at steady state (AUCss) using F06 Formulation administered via feeding tube
時間枠:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
AUC at steady state (AUCss) using minitablets/F15
時間枠:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Terminal half life (t½) using F1 Formulation
時間枠:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Terminal half life (t½) using F06 Formulation given intact
時間枠:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Terminal half life (t½) using F06 Formulation administered via feeding tube
時間枠:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Terminal half life (t½) using minitablets/F15
時間枠:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Area under the drug concentration by time curve (AUC) using F1 Formulation
時間枠:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Area under the drug concentration by time curve (AUC) using F06 Formulation given intact
時間枠:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Area under the drug concentration by time curve (AUC) using F06 Formulation administered via feeding tube
時間枠:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Area under the drug concentration by time curve (AUC) using minitablets/F15
時間枠:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Cohort A, D, or E: Clinical Benefit Rate (CBR)
時間枠:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: CBR
時間枠:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: CBR
時間枠:Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Cohort A, D, or E: Progression-free Survival (PFS)
時間枠:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: PFS
時間枠:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: PFS
時間枠:Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Cohort A, D, or E: Overall Survival (OS)
時間枠:Approximately 6 months

Assessed by RECIST v1.1

Approximately 6 months
Cohort B or E: OS
時間枠:Approximately 6 months

Assessed by RANO

Approximately 6 months
Cohort A, D, or E: ORR
時間枠:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: ORR
時間枠:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: ORR
時間枠:Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Cohort A, D, or E: Time to response (TTR)
時間枠:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: TTR
時間枠:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: TTR
時間枠:Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Cohort A, D, or E: Duration of Response (DOR)
時間枠:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: DOR
時間枠:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: DOR
時間枠:Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR
時間枠:Approximately 6 months

Assessed by RANO per the investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): ORR
時間枠:Approximately 6 months

Assessed by RECIST v1.1 per the investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): ORR
時間枠:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): ORR
時間枠:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): ORR
時間枠:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): ORR
時間枠:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): ORR
時間枠:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR
時間枠:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR
時間枠:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): DOR
時間枠:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): DOR
時間枠:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): DOR
時間枠:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): DOR
時間枠:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): DOR
時間枠:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): DOR
時間枠:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR
時間枠:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR
時間枠:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): TTR
時間枠:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): TTR
時間枠:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): TTR
時間枠:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): TTR
時間枠:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): TTR
時間枠:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): TTR
時間枠:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR
時間枠:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Clinical Trials、Hoffmann-La Roche

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2016年5月3日

一次修了 (推定)

2027年6月30日

研究の完了 (推定)

2027年6月30日

試験登録日

最初に提出

2016年1月4日

QC基準を満たした最初の提出物

2016年1月7日

最初の投稿 (推定)

2016年1月8日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月23日

QC基準を満たした最後の更新が送信されました

2026年9月18日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • RXDX-101-03
  • CO40778 (その他の識別子:Hoffmann-La Roche)
  • 2023-505088-35-00 (Ctis)
  • 2023 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing.

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する